TABLE 2.
Medication adherence for each group in the PP analysis.
| VDF-triple (N = 144) | VDA-triple (N = 145) | EBDF-quadruple (N = 140) | EBDA-quadruple (N = 133) | p-value (VDF-triple VS. VDA-triple) | p-value (EBDF-quadruple VS. EBDA-quadruple) | p-value (VDF-triple VS. EBDF-quadruple) | p-value (VDA-triple VS. EBDA-quadruple) | |
|---|---|---|---|---|---|---|---|---|
| MMAS-8 score | 7.02 ± 0.83 | 7.21 ± 0.73 | 7.00 ± 0.82 | 7.07 ± 0.78 | 0.053 | 0.451 | 0.722 | 0.121 |
| MMAS-8 assessment | — | — | — | — | 0.406 | 0.785 | 0.371 | 0.561 |
| Low | 21 (14.58%) | 14 (9.66%) | 21 (14.58%) | 14 (9.66%) | — | — | — | — |
| Medium | 115 (79.86%) | 124 (85.52%) | 115 (79.86%) | 124 (85.52%) | — | — | — | — |
| High | 8 (5.56%) | 7 (4.83%) | 8 (5.56%) | 7 (4.83%) | — | — | — | — |
| Tablets counting | — | — | — | — | 0.980 | 0.956 | 0.365 | 0.335 |
| ≥90% | 122 (84.72%) | 123 (84.83%) | 122 (84.72%) | 123 (84.83%) | — | — | — | — |
| <90% | 22 (15.28%) | 22 (15.17%) | 22 (15.28%) | 22 (15.17%) | — | — | — | — |
Note: VDF-triple, VPZ + Furazolidone + Doxycycline; VDA-triple, VPZ + Amoxicillin + Doxycycline; EBDF-quadruple, EPZ + Colloidal bismuth tartrate + Furazolidone + Doxycycline; EBDA-quadruple, EPZ + Colloidal bismuth tartrate + Amoxicillin + Doxycycline.